Description: Accelerating 1st-in-class therapies for inflammatory and rare diseases with unprecedented efficiency
GEn1E is honored to have been selected as the Rising Star winner for New Health Application of AI by UCSF's Digital Health Awards 2022
Multiple-mechanism-of-action protein targets enable us to develop novel therapies for inflammatory diseases. Our focus is on those devastating diseases which currently have no effective treatment, cause suffering to millions of patients and their families and cost society billions of dollars.
ARDS is an acute diffuse, inflammatory lung injury, leading to increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue. In ARDS, fluid leaks into lungs making it difficult to absorb oxygen and the patient cannot breathe